PURPOSE: Ovarian cancer is the leading cause of death among all gynecological malignancies in Western countries. Although therapy for ovarian cancer has been greatly improved in the past 20 years, the overall survival for patients with advanced ovarian cancer has not changed significantly. The poor survival rates in patients with advanced ovarian cancer are due both to late diagnosis and to lack of effective drugs for the majority of patients who have a relapse and develop resistance to current chemotherapy agents used for ovarian cancer. Thus, developing and discovering effective novel drugs with different molecular structures from conventional chemotherapy agents have become an urgent clinical need. METHODS: Ovarian cancer cells were treated with lovastatin and atorvastatin. Apoptosis in these cells and tumor formation in soft agar were determined. The molecular mechanism by which statins suppress ovarian cancer cell growth was evaluated. RESULTS: Both lovastatin and atorvastatin effectively induced apoptosis in ovarian cancer cells and suppressed anchorage-independent growth of these cells in soft agar. Further investigation of the molecular mechanism has revealed that the expression of Cdc42 and Rac1, small GTPase family members, was highly induced in the cells by these statins along with the activation of Jun N-terminal kinases (JNK). In addition, Bim, a proapoptotic protein, was significantly induced by these statins. CONCLUSIONS: Our findings provide new insight into the molecular mechanism by which statins induce apoptosis in ovarian cancer cells and may lead to novel therapies for advanced ovarian cancer.
PURPOSE:Ovarian cancer is the leading cause of death among all gynecological malignancies in Western countries. Although therapy for ovarian cancer has been greatly improved in the past 20 years, the overall survival for patients with advanced ovarian cancer has not changed significantly. The poor survival rates in patients with advanced ovarian cancer are due both to late diagnosis and to lack of effective drugs for the majority of patients who have a relapse and develop resistance to current chemotherapy agents used for ovarian cancer. Thus, developing and discovering effective novel drugs with different molecular structures from conventional chemotherapy agents have become an urgent clinical need. METHODS:Ovarian cancer cells were treated with lovastatin and atorvastatin. Apoptosis in these cells and tumor formation in soft agar were determined. The molecular mechanism by which statins suppress ovarian cancer cell growth was evaluated. RESULTS: Both lovastatin and atorvastatin effectively induced apoptosis in ovarian cancer cells and suppressed anchorage-independent growth of these cells in soft agar. Further investigation of the molecular mechanism has revealed that the expression of Cdc42 and Rac1, small GTPase family members, was highly induced in the cells by these statins along with the activation of Jun N-terminal kinases (JNK). In addition, Bim, a proapoptotic protein, was significantly induced by these statins. CONCLUSIONS: Our findings provide new insight into the molecular mechanism by which statins induce apoptosis in ovarian cancer cells and may lead to novel therapies for advanced ovarian cancer.
Authors: Hannah M Jones; Ziwei Fang; Wenchuan Sun; Leslie H Clark; Jessica E Stine; Arthur-Quan Tran; Stephanie A Sullivan; Timothy P Gilliam; Chunxiao Zhou; Victoria L Bae-Jump Journal: Am J Cancer Res Date: 2017-12-01 Impact factor: 6.166
Authors: Andreas Link; Simina Selejan; Lisa Hewera; Felix Walter; Georg Nickenig; Michael Böhm Journal: Clin Res Cardiol Date: 2010-09-19 Impact factor: 5.460
Authors: Clary B Clish; Shelley S Tworoger; Oana A Zeleznik; A Heather Eliassen; Peter Kraft; Elizabeth M Poole; Bernard A Rosner; Sarah Jeanfavre; Amy A Deik; Kevin Bullock; Daniel S Hitchcock; Julian Avila-Pacheco Journal: Cancer Res Date: 2020-01-22 Impact factor: 12.701